TRAW

Traws Pharma, Inc. TRAW

NasdaqSmall CapHealthcare

13F Pro quality score

Rank #2,839 of 2,925

Why it scores 14Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Top Institutional Holders

as of Q2 2026
$5.19M total
ORBIMED ADVISORS LLC
$1.01M+98.7%
Ally Bridge Group (NY) LLC
$663.0KNew
ADAGE CAPITAL PARTNERS GP, L.L.C.
$615.6K0.0%
ADAR1 Capital Management, LLC
$504.1K+287.9%
Lynx1 Capital Management LP
$471.8K+3610.5%
Ikarian Capital, LLC
$403.2K-29.5%
SPHERA FUNDS MANAGEMENT LTD.
$336.0KNew
VANGUARD CAPITAL MANAGEMENT LLC
$278.2K+498.0%
JANE STREET GROUP, LLC
$182.2K+916.9%
Alyeska Investment Group, L.P.
$138.6KNew
BOOTHBAY FUND MANAGEMENT, LLC
$112.9K-31.2%
GEODE CAPITAL MANAGEMENT, LLC
$93.9K+44.4%
HRT FINANCIAL LP
$76.0KNew
Kynam Capital Management, LP
$71.2KNew
Dauntless Investment Group, LLC
$67.9K-80.7%
VANGUARD FIDUCIARY TRUST CO
$46.0K+71.4%
NORTHERN TRUST CORP
$31.6KNew
STATE STREET CORP
$21.8K0.0%
XTX Topco Ltd
$15.3KNew
SG Americas Securities, LLC
$12.0KNew
Virtu Financial LLC
$11.0KNew
BlackRock, Inc.
$8.4K-0.2%
Tower Research Capital LLC (TRC)
$4.3K+29.7%
HUNTINGTON NATIONAL BANK
$3.9KNew
UBS Group AG
$2.9K-14.9%
See all 34 institutional holders →
Reading the latest SEC filing…

Key Metrics

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/TRAW

Earnings Per Share

13fpro.ai/company/TRAW

Loading ratio trend…

TRAW key financials by period

Reported revenue, net income and operating margin by fiscal year, from Traws Pharma, Inc.'s annual filings on SEC EDGAR.

Traws Pharma, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$2.8M$9.2M—
FY 2024$226.0K$-166.5M—
FY 2023$226.0K$-18.9M—
FY 2022$226.0K$-19.0M—
FY 2021$226.0K$-16.2M—
FY 2020$231.0K$-25.2M—
Source: TRAW filings on SEC EDGAR →

TRAW insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Traws Pharma, Inc. (TRAW): stock profile, AI score and financials

Traws Pharma, Inc. (TRAW) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores TRAW at 13.5/100 on a composite quality score built from its SEC filings, placing it at rank #2,839 of 2,925 stocks — the bottom half of the AI-ranked universe. Top institutional holders of TRAW by reported 13-F value include ORBIMED ADVISORS, Ally Bridge Group (NY), ADAGE CAPITAL PARTNERS GP, L.L.C., based on the most recent SEC filings. TRAW trades on the Nasdaq exchange and files with the SEC under CIK 1130598. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TRAW daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Traws Pharma, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1130598 →